A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages
Neuroimaging has made it possible to measure pathological brain changes associated with
Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been …
Alzheimer's disease (AD) in vivo. Over the past decade, these measures have been …
[HTML][HTML] The blood-brain barrier in Alzheimer's disease
E Zenaro, G Piacentino, G Constantin - Neurobiology of disease, 2017 - Elsevier
Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by the
pathological accumulation of amyloid beta (Aβ) peptides and neurofibrillary tangles …
pathological accumulation of amyloid beta (Aβ) peptides and neurofibrillary tangles …
[18F]FDG PET signal is driven by astroglial glutamate transport
Contributions of glial cells to neuroenergetics have been the focus of extensive debate. Here
we provide positron emission tomography evidence that activation of astrocytic glutamate …
we provide positron emission tomography evidence that activation of astrocytic glutamate …
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts
U Saeed, J Compagnone, RI Aviv, AP Strafella… - Translational …, 2017 - Springer
Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …
Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV
M Aghourian, C Legault-Denis, JP Soucy… - Molecular …, 2017 - nature.com
Abstract 18 F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to
the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was …
the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was …
The diagnostic value of FDG and amyloid PET in Alzheimer's disease—A systematic review
L Rice, S Bisdas - European journal of radiology, 2017 - Elsevier
Purpose By 2050 it is projected that 115 million people worldwide will have Alzheimer's
Disease (AD)[1]. Recent attempts have been made to redefine the diagnostic criteria of AD …
Disease (AD)[1]. Recent attempts have been made to redefine the diagnostic criteria of AD …
Blood-brain glucose transfer in Alzheimer's disease: effect of GLP-1 analog treatment
There are fewer than normal glucose transporters at the blood-brain barrier (BBB) in
Alzheimer's disease (AD). When reduced expression of transporters aggravates the …
Alzheimer's disease (AD). When reduced expression of transporters aggravates the …
Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery
After advanced age, female sex is the major risk factor for Alzheimer's disease (AD). The
biological mechanisms underlying the increased AD risk in women remain largely …
biological mechanisms underlying the increased AD risk in women remain largely …
Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease
AE Leeuwis, MR Benedictus, JPA Kuijer… - Alzheimer's & …, 2017 - Elsevier
Introduction We examined the association between decreased cerebral blood flow (CBF)
and cognitive impairment in Alzheimer's disease (AD), mild cognitive impairment (MCI), and …
and cognitive impairment in Alzheimer's disease (AD), mild cognitive impairment (MCI), and …
Independent component analysis-support vector machine-based computer-aided diagnosis system for Alzheimer's with visual support
Computer-aided diagnosis (CAD) systems constitute a powerful tool for early diagnosis of
Alzheimer's disease (AD), but limitations on interpretability and performance exist. In this …
Alzheimer's disease (AD), but limitations on interpretability and performance exist. In this …